250 related articles for article (PubMed ID: 37699890)
21. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
Seekircher L; Bánki Z; Kimpel J; Rössler A; Schäfer H; Falkensammer B; Bante D; Forer L; Schönherr S; ; Harthaller T; Sacher M; Ower C; Tschiderer L; Ulmer H; Krammer F; von Laer D; Borena W; Willeit P
Lancet Microbe; 2023 Aug; 4(8):e612-e621. PubMed ID: 37354911
[TBL] [Abstract][Full Text] [Related]
22. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
[TBL] [Abstract][Full Text] [Related]
24. Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
Tani N; Ikematsu H; Goto T; Kondo S; Gondo K; Fujiyoshi N; Minami J; Harada Y; Nagano S; Horiuchi T; Kuwano H; Akashi K; Shimono N; Chong Y
Vaccine; 2023 Oct; 41(45):6672-6678. PubMed ID: 37775465
[TBL] [Abstract][Full Text] [Related]
25. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
Miyamoto S; Suzuki T
Vaccine; 2024 Feb; 42(6):1401-1406. PubMed ID: 38310015
[TBL] [Abstract][Full Text] [Related]
26. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults.
Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA
Front Immunol; 2022; 13():882918. PubMed ID: 35958601
[TBL] [Abstract][Full Text] [Related]
27. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.
Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Kalikawe R; Datwani S; Waterworth R; Umviligihozo G; Ennis S; Young L; Dong W; Kirkby D; Burns L; Leung V; Holmes DT; DeMarco ML; Simons J; Matic N; Montaner JSG; Brumme CJ; Prystajecky N; Niikura M; Lowe CF; Romney MG; Brockman MA; Brumme ZL
Front Immunol; 2022; 13():947021. PubMed ID: 36148225
[TBL] [Abstract][Full Text] [Related]
28. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination.
Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A
Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677
[TBL] [Abstract][Full Text] [Related]
29. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
30. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.
Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ
Front Immunol; 2023; 14():1120556. PubMed ID: 36936965
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity.
Nantel S; Sheikh-Mohamed S; Chao GYC; Kurtesi A; Hu Q; Wood H; Colwill K; Li Z; Liu Y; Seifried L; Bourdin B; McGeer A; Hardy WR; Rojas OL; Al-Aubodah TA; Liu Z; Ostrowski MA; Brockman MA; Piccirillo CA; Quach C; Rini JM; Gingras AC; Decaluwe H; Gommerman JL
Mucosal Immunol; 2024 Apr; 17(2):201-210. PubMed ID: 38278415
[TBL] [Abstract][Full Text] [Related]
32. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
34. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S; Arashiro T; Adachi Y; Moriyama S; Kinoshita H; Kanno T; Saito S; Katano H; Iida S; Ainai A; Kotaki R; Yamada S; Kuroda Y; Yamamoto T; Ishijima K; Park ES; Inoue Y; Kaku Y; Tobiume M; Iwata-Yoshikawa N; Shiwa-Sudo N; Tokunaga K; Ozono S; Hemmi T; Ueno A; Kishida N; Watanabe S; Nojima K; Seki Y; Mizukami T; Hasegawa H; Ebihara H; Maeda K; Fukushi S; Takahashi Y; Suzuki T
Med; 2022 Apr; 3(4):249-261.e4. PubMed ID: 35261995
[TBL] [Abstract][Full Text] [Related]
35. Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study.
Breznik JA; Rahim A; Bhakta H; Clare R; Zhang A; Ang J; Stacey HD; Liu LM; Kennedy A; Bilaver L; Hagerman M; Kajaks T; Bramson JL; Nazy I; Miller MS; Costa AP; Bowdish DME;
J Med Virol; 2023 Oct; 95(10):e29170. PubMed ID: 37822054
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.
Zens KD; Llanas-Cornejo D; Menges D; Fehr JS; Münz C; Puhan MA; Frei A
Int J Infect Dis; 2023 Aug; 133():18-26. PubMed ID: 37149211
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
Servellita V; Syed AM; Morris MK; Brazer N; Saldhi P; Garcia-Knight M; Sreekumar B; Khalid MM; Ciling A; Chen PY; Kumar GR; Gliwa AS; Nguyen J; Sotomayor-Gonzalez A; Zhang Y; Frias E; Prostko J; Hackett J; Andino R; Wadford DA; Hanson C; Doudna J; Ott M; Chiu CY
Cell; 2022 Apr; 185(9):1539-1548.e5. PubMed ID: 35429436
[TBL] [Abstract][Full Text] [Related]
38. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
39. Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin.
Pušnik J; Zorn J; Monzon-Posadas WO; Peters K; Osypchuk E; Blaschke S; Streeck H
Nat Commun; 2024 Apr; 15(1):3102. PubMed ID: 38600072
[TBL] [Abstract][Full Text] [Related]
40. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
